Amylyx Pharmaceuticals, Inc. will present at a conference and provide a corporate update, including information on the commercial launch of RELYVRIO in the U.S., which is expected to exceed revenue estimates. They will also provide updates on access and insurance coverage, EU approval for AMX0035, and the completion of enrollment in the PHOENIX clinical trial.